Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 24Nivolumab 23aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Biopsy 7dabrafenib 6Surveys and Questionnaires 6Dacarbazine 6trametinib 5binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Blood Specimen Collection 5Aminolevulinic Acid 5sonidegib 4encorafenib 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Educational Status 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × tozuleristide × Dermatologic × Clear all
NCT02097875 2015-04-21

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Blaze Bioscience Australia Pty Ltd

Phase 1 Completed
21 enrolled
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡